

# Rajesh Pahwa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10064518/publications.pdf>

Version: 2024-02-01

125  
papers

9,327  
citations

53751

45  
h-index

39638

94  
g-index

127  
all docs

127  
docs citations

127  
times ranked

6331  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 69-81.	1.2	1
2	<scp>THN</scp> 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. <i>Movement Disorders</i> , 2022, 37, 410-415.	2.2	6
3	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries. <i>Neurology and Therapy</i> , 2022, 11, 303-318.	1.4	6
4	Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses. <i>Neurology and Therapy</i> , 2022, , .	1.4	1
5	Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2022, , .	1.6	0
6	Cognitive workload during verbal abstract reasoning in Parkinson's disease: a pilot study. <i>International Journal of Neuroscience</i> , 2021, 131, 504-510.	0.8	3
7	Reliability and Validity of Pupillary Response During Dual-Task Balance in Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 448-455.	0.5	9
8	Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson's Disease. <i>Touch Reviews in Neurology</i> , 2021, 17, 36.	0.1	1
9	Exploring essential tremor: Results from a large online survey. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2021, 5, 100101.	0.5	2
10	Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 645706.	1.1	17
11	A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of <scp>CX</scp> in Essential Tremor. <i>Movement Disorders</i> , 2021, 36, 1944-1949.	2.2	18
12	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021, 10, 307-320.	1.4	9
13	Pupillary Response to Postural Demand in Parkinson's Disease. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 617028.	2.0	6
14	Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 52-57.	1.1	2
15	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on "Off"-time in Patients with Advanced Parkinson's Disease: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 2854-2890.	1.3	41
16	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	3.8	80
17	Amantadine: an old drug reborn. <i>Lancet Neurology</i> , The, 2021, 20, 975-977.	4.9	7
18	Dyskinesia Matters. <i>Movement Disorders</i> , 2020, 35, 392-396.	2.2	42

#	ARTICLE	IF	CITATIONS
19	Does post-operative symptomatic lead edema associated with subthalamic DBS implantation impact long-term clinical outcomes?. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116647.	0.3	10
20	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	4.9	80
21	Classification of Parkinson's disease and essential tremor based on balance and gait characteristics from wearable motion sensors via machine learning techniques: a data-driven approach. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020, 17, 125.	2.4	68
22	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. <i>Movement Disorders</i> , 2020, 35, 901-901.	2.2	0
23	Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 63-71.	1.1	39
24	Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraph®. <i>Journal of Clinical Movement Disorders</i> , 2020, 7, 5.	2.2	17
25	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 543-558.	1.5	20
26	Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. <i>Lancet Neurology</i> , The, 2020, 19, 491-501.	4.9	88
27	Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 29.	1.1	35
28	Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	2
29	Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. <i>Clinical Pharmacokinetics</i> , 2019, 58, 77-88.	1.6	35
30	Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. <i>Advances in Therapy</i> , 2019, 36, 2233-2246.	1.3	25
31	Brain activity during dual task gait and balance in aging and age-related neurodegenerative conditions: A systematic review. <i>Experimental Gerontology</i> , 2019, 128, 110756.	1.2	43
32	An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. <i>Neuromodulation</i> , 2019, 22, 537-545.	0.4	52
33	Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 681-691.	1.3	5
34	Old Drugs, New Delivery Systems in Parkinson's Disease. <i>Drugs and Aging</i> , 2019, 36, 807-821.	1.3	15
35	Extended-Release Amantadine for Levodopa-Induced Dyskinesia. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 293-299.	1.4	8
36	Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75 years of age. <i>Journal of the Neurological Sciences</i> , 2019, 399, 57-60.	0.3	12

#	ARTICLE	IF	CITATIONS
37	Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor. <i>Sensors</i> , 2019, 19, 5153.	2.1	33
38	Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 126-132.	1.1	37
39	Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 118-125.	1.1	21
40	Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , 2019, 18, 145-154.	4.9	82
41	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 183-190.	0.8	15
42	The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. <i>Neurodegenerative Disease Management</i> , 2018, 8, 73-80.	1.2	16
43	Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 155-161.	0.7	26
44	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , 2018, 23, 402-413.	0.7	8
45	Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 665-673.	0.9	27
46	Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 669-680.	1.4	42
47	Pupillary Response to Cognitive Demand in Parkinson's Disease: A Pilot Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 90.	1.7	10
48	Outpatient titration of carbidopa/levodopa enteral suspension (Duopa). <i>International Journal of Neuroscience</i> , 2017, 127, 459-465.	0.8	6
49	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study). <i>JAMA Neurology</i> , 2017, 74, 941.	4.5	137
50	Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 18-26.	1.1	59
51	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 216.	4.5	171
52	Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 383, 42-46.	0.3	23
53	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). <i>Movement Disorders</i> , 2017, 32, 1701-1709.	2.2	134
54	National randomized controlled trial of virtual house calls for Parkinson disease. <i>Neurology</i> , 2017, 89, 1152-1161.	1.5	169

#	ARTICLE	IF	CITATIONS
55	ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. JAMA Neurology, 2017, 74, 1507.	4.5	12
56	Clinical utility of DaTscan, SPECT imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Review of Neurotherapeutics, 2017, 17, 219-225.	1.4	22
57	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. Journal of Parkinson's Disease, 2017, 7, 511-522.	1.5	42
58	Tremor: Phenomenology, Etiology, Diagnosis, and Treatment. , 2017, , 303-314.		0
59	Deep brain stimulation for Parkinson's disease: current status and future outlook. Neurodegenerative Disease Management, 2016, 6, 299-317.	1.2	4
60	The characterization of a base-width neutral step as the first step for balance recovery in moderate Parkinson's disease. International Journal of Neuroscience, 2016, 126, 713-722.	0.8	0
61	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemedicine Journal and E-Health, 2016, 22, 590-598.	1.6	47
62	Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Movement Disorders, 2015, 30, 788-795.	2.2	123
63	Paradoxical Effect of Dopamine Medication on Cognition in Parkinson's Disease: Relationship to Side of Motor Onset. Journal of the International Neuropsychological Society, 2015, 21, 259-270.	1.2	29
64	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. Journal of the American Medical Directors Association, 2015, 16, 898.e1-898.e7.	1.2	46
65	Treatment of early Parkinson's disease. Current Opinion in Neurology, 2014, 27, 442-449.	1.8	33
66	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
67	Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 142-148.	1.1	76
68	Deep brain stimulation for essential tremor. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 155-166.	1.0	37
69	Deep brain stimulation. , 2013, , 478-495.		0
70	Beneficial Effects of Green Tea Consumption in Parkinson's Disease Patients. FASEB Journal, 2013, 27, 368.1.	0.2	0
71	Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor. Journal of Neurosurgery, 2012, 117, 156-161.	0.9	59
72	Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia. Journal of the Neurological Sciences, 2012, 319, 24-31.	0.3	34

#	ARTICLE	IF	CITATIONS
73	Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 140-149.	4.9	354
74	Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. <i>American Journal of Managed Care</i> , 2010, 16 Suppl Implications, S94-9.	0.8	25
75	Levodopa-related wearing-off in Parkinson's disease: identification and management. <i>Current Medical Research and Opinion</i> , 2009, 25, 841-849.	0.9	76
76	Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease<sub>title</sub>A Randomized Controlled Trial<sub>title</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 63.	3.8	1,253
77	Deep Brain Stimulation and Tremor. <i>Neurotherapeutics</i> , 2008, 5, 331-338.	2.1	122
78	Pharmacotherapy of Essential Tremor. <i>CNS Drugs</i> , 2008, 22, 1037-1045.	2.7	226
79	Effect of Behavioral Intervention on Comorbid General Anxiety Disorder and Parkinson's Disease. <i>Clinical Gerontologist</i> , 2008, 32, 104-117.	1.2	4
80	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study). <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2008, 3, .	0.0	0
81	Thalamic Deep Brain Stimulation and Essential Tremor. , 2008, , 205-214.		0
82	Thalamic Deep Brain Stimulation for Parkinson's Disease Tremor. , 2008, , 229-241.		2
83	A stimulating treatment for essential tremor. , 2008, , 321-323.		0
84	Subthalamic Nucleus Stimulation in Parkinson's Disease Patients Intolerant to Levodopa. <i>Stereotactic and Functional Neurosurgery</i> , 2007, 85, 169-174.	0.8	11
85	Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of "off" episodes in patients with Parkinson's disease. <i>Current Medical Research and Opinion</i> , 2007, 23, 741-750.	0.9	27
86	Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. <i>Journal of the Neurological Sciences</i> , 2007, 258, 137-143.	0.3	76
87	Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. <i>Neurology</i> , 2007, 68, 1262-1267.	1.5	256
88	Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. <i>Journal of Neurosurgery</i> , 2006, 104, 502-505.	0.9	84
89	Long-term evaluation of deep brain stimulation of the thalamus. <i>Journal of Neurosurgery</i> , 2006, 104, 506-512.	0.9	325
90	Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 461-464.	0.6	62

#	ARTICLE	IF	CITATIONS
91	Stimulation of the motor cortex for disabling essential tremor. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 564-567.	0.6	8
92	Postural tremor suppression is dependent on thalamic stimulation frequency. <i>Movement Disorders</i> , 2006, 21, 1290-1292.	2.2	25
93	Deep brain stimulation: Preoperative issues. <i>Movement Disorders</i> , 2006, 21, S171-S196.	2.2	260
94	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006, 21, S290-S304.	2.2	811
95	Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. <i>Journal of Neurosurgery</i> , 2005, 103, 252-255.	0.9	70
96	Quality of life in Essential Tremor Questionnaire (QUEST): Development and initial validation. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 367-373.	1.1	157
97	Preoperative Clinical Predictors of Response to Bilateral Subthalamic Stimulation in Patients with Parkinson's Disease. <i>Stereotactic and Functional Neurosurgery</i> , 2005, 83, 80-83.	0.8	68
98	Deep brain stimulation in Parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 290-295.	2.0	31
99	Ropinirole therapy for Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 581-588.	1.4	20
100	Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. <i>Neurologic Clinics</i> , 2004, 22, S35-S52.	0.8	7
101	Presurgical Coping, Depression, and Quality of Life in Persons with Parkinson's Disease. <i>Journal of Clinical Psychology in Medical Settings</i> , 2003, 10, 101-107.	0.8	14
102	Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study. <i>Movement Disorders</i> , 2003, 18, 584-587.	2.2	30
103	Benefits and Risks of Pharmacological Treatments for Essential Tremor. <i>Drug Safety</i> , 2003, 26, 461-481.	1.4	94
104	Essential tremor: differential diagnosis and current therapy. <i>American Journal of Medicine</i> , 2003, 115, 134-142.	0.6	102
105	Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. <i>Journal of Neurosurgery</i> , 2003, 99, 71-77.	0.9	120
106	Long-Term Efficacy of Globus pallidus Stimulation for the Treatment of Parkinson's Disease. <i>Stereotactic and Functional Neurosurgery</i> , 2002, 79, 214-220.	0.8	35
107	Thalamic stimulation for midbrain tremor after partial hemangioma resection. <i>Movement Disorders</i> , 2002, 17, 404-407.	2.2	41
108	Transdermal dopaminergic D2receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2001, 16, 459-463.	2.2	54

#	ARTICLE	IF	CITATIONS
109	Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. <i>Movement Disorders</i> , 2001, 16, 464-468.	2.2	266
110	Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. <i>Movement Disorders</i> , 2001, 16, 140-143.	2.2	163
111	Efficacy of unilateral deep brain stimulation of the vim nucleus of the thalamus for essential head tremor. <i>Movement Disorders</i> , 1999, 14, 847-850.	2.2	134
112	Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience. <i>Movement Disorders</i> , 1998, 13, 377-382.	2.2	105
113	Double-blind controlled trial of gabapentin in essential tremor. <i>Movement Disorders</i> , 1998, 13, 465-467.	2.2	120
114	Improvements in daily functioning after deep brain stimulation of the thalamus for intractable tremor. <i>Movement Disorders</i> , 1998, 13, 690-692.	2.2	55
115	Cognitive impairment in Parkinson's disease. <i>European Journal of Neurology</i> , 1998, 5, 431-441.	1.7	24
116	Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1997, 20, 523-530.	0.2	71
117	Analysis of Pallidotomy Lesion Positions Using Three-dimensional Reconstruction of Pallidal Lesions, the Basal Ganglia, and the Optic Tract. <i>Neurosurgery</i> , 1997, 41, 1303-1318.	0.6	52
118	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997, 42, 292-299.	2.8	508
119	Effects of thalamic deep brain stimulation based on tremor type and diagnosis. <i>Movement Disorders</i> , 1997, 12, 337-341.	2.2	80
120	Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in parkinson's disease: Pharmacokinetic and quality-of-life measures. <i>Movement Disorders</i> , 1997, 12, 677-681.	2.2	28
121	Diabetes mellitus presenting as paroxysmal kinesigenic dystonic choreoathetosis. <i>Movement Disorders</i> , 1995, 10, 353-355.	2.2	33
122	Interactive video conferencing: A means of providing interim care to parkinson's disease patients. <i>Movement Disorders</i> , 1993, 8, 380-382.	2.2	141
123	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD-Adjunct Study). , 0, , 73-84.		0
124	Managing essential tremor patients treated with deep brain stimulation. , 0, , 56-61.		0
125	Managing essential tremor patients treated with deep brain stimulation. , 0, , 77-83.		0